Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Maintenance in Advanced Gastric Cancer
NCT02537171Phase 3Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Jul 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by 307 Hospital of the People's Liberation Army. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02537171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537171.